Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
NexImmune revenue
NexImmune's revenue is $31.0 million.
What is NexImmune's revenue?
- NexImmune has 1,942 employees, and the revenue per employee ratio is $15,945.
- NexImmune peak revenue was $31.0M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
NexImmune financing
NexImmune received early financing of $1.0K on 2012-02-02.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $1K | 02/2012 |
| Series Unknown | $3M | 07/2014 |
| Series A | $23M | 01/2018 |
| Series Unknown | $7.8M | 02/2019 |
| Convertible Note | $50M | 01/2021 |
| Post Ipo Equity | $126.5M | 02/2021 |
NexImmune investors
| Investors | Security type |
|---|---|
| New Enterprise Associates (NEA) | Series Unknown |
| Pfizer Venture Investments | Series Unknown |
| Amgen | Series Unknown |
| Barer & Son Capital | Series A |
| Piedmont Capital Partners | Series A |
| ArrowMark Partners | Series A |
| Irving Investors | Convertible Note |
NexImmune competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Fate Therapeutics | - | $13.6M | 104 | - |
| BioTime | - | $3.4M | 101 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Trillium Therapeutics | - | $148,000 | 20 | - |
| INmune Bio | - | $14,000 | 5 | - |
| Immune Therapeutics | - | $113,500 | 2 | - |
| Cue Biopharma | - | $9.3M | 46 | - |
| Genocea | - | - | 59 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of NexImmune, including salaries, political affiliations, employee data, and more, in order to inform job seekers about NexImmune. The employee data is based on information from people who have self-reported their past or current employments at NexImmune. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by NexImmune. The data presented on this page does not represent the view of NexImmune and its employees or that of Zippia.
NexImmune may also be known as or be related to NexImmune, NexImmune Inc, NexImmune Inc., NexImmune, Inc., Neximmune, Inc. and neximmune.